Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.

Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N, Olsen DB, Goodwin M, Sutphin M, Weiner DM, Via LE, Boshoff HIM, Barry CE 3rd.

J Med Chem. 2018 Nov 5. doi: 10.1021/acs.jmedchem.8b00883. [Epub ahead of print]

PMID:
30350998
2.

Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific.

Guerrini V, Prideaux B, Blanc L, Bruiners N, Arrigucci R, Singh S, Ho-Liang HP, Salamon H, Chen PY, Lakehal K, Subbian S, O'Brien P, Via LE, Barry CE 3rd, Dartois V, Gennaro ML.

PLoS Pathog. 2018 Aug 30;14(8):e1007223. doi: 10.1371/journal.ppat.1007223. eCollection 2018 Aug.

3.

The present state of the tuberculosis drug development pipeline.

J Libardo MD, Boshoff HI, Barry CE 3rd.

Curr Opin Pharmacol. 2018 Oct;42:81-94. doi: 10.1016/j.coph.2018.08.001. Epub 2018 Aug 23. Review.

PMID:
30144650
4.

A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images.

Malherbe ST, Dupont P, Kant I, Ahlers P, Kriel M, Loxton AG, Chen RY, Via LE, Thienemann F, Wilkinson RJ, Barry CE 3rd, Griffith-Richards S, Ellman A, Ronacher K, Winter J, Walzl G, Warwick JM; Catalysis Biomarker Consortium.

EJNMMI Res. 2018 Jun 25;8(1):55. doi: 10.1186/s13550-018-0411-7.

5.

Construction of Fluorescent Analogs to Follow the Uptake and Distribution of Cobalamin (Vitamin B12) in Bacteria, Worms, and Plants.

Lawrence AD, Nemoto-Smith E, Deery E, Baker JA, Schroeder S, Brown DG, Tullet JMA, Howard MJ, Brown IR, Smith AG, Boshoff HI, Barry CE 3rd, Warren MJ.

Cell Chem Biol. 2018 Aug 16;25(8):941-951.e6. doi: 10.1016/j.chembiol.2018.04.012. Epub 2018 May 17.

PMID:
29779954
6.

Transmission of Mycobacterium tuberculosis From Patients Who Are Nucleic Acid Amplification Test Negative.

Xie YL, Cronin WA, Proschan M, Oatis R, Cohn S, Curry SR, Golub JE, Barry CE 3rd, Dorman SE.

Clin Infect Dis. 2018 Nov 13;67(11):1653-1659. doi: 10.1093/cid/ciy365.

PMID:
29697779
7.

2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization.

Murugesan D, Ray PC, Bayliss T, Prosser GA, Harrison JR, Green K, Soares de Melo C, Feng TS, Street LJ, Chibale K, Warner DF, Mizrahi V, Epemolu O, Scullion P, Ellis L, Riley J, Shishikura Y, Ferguson L, Osuna-Cabello M, Read KD, Green SR, Lamprecht DA, Finin PM, Steyn AJC, Ioerger TR, Sacchettini J, Rhee KY, Arora K, Barry CE 3rd, Wyatt PG, Boshoff HIM.

ACS Infect Dis. 2018 Jun 8;4(6):954-969. doi: 10.1021/acsinfecdis.7b00275. Epub 2018 Mar 26.

8.

Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, Nuermberger E, Kim P, Barry CE, Owen A, Hazuda D, Flexner C.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):125-132. doi: 10.5588/ijtld.17.0486.

9.

Role of Chemical Biology in Tuberculosis Drug Discovery and Diagnosis.

Kolbe K, Veleti SK, Johnson EE, Cho YW, Oh S, Barry CE 3rd.

ACS Infect Dis. 2018 Apr 13;4(4):458-466. doi: 10.1021/acsinfecdis.7b00242. Epub 2018 Feb 7.

PMID:
29364647
10.

Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis.

Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Horswell S, Coussens AK, Barry CE 3rd, O'Garra A, Wilkinson RJ.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E964-E973. doi: 10.1073/pnas.1711853115. Epub 2018 Jan 16.

11.

Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium.

Nat Med. 2017 Dec 7;23(12):1499. doi: 10.1038/nm1217-1499a.

12.

Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.

Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA, Barry CE 3rd, Dartois VA.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02266-17. doi: 10.1128/AAC.02266-17. Print 2018 Feb.

13.

Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.

Wilson CR, Gessner RK, Moosa A, Seldon R, Warner DF, Mizrahi V, Soares de Melo C, Simelane SB, Nchinda A, Abay E, Taylor D, Njoroge M, Brunschwig C, Lawrence N, Boshoff HIM, Barry CE 3rd, Sirgel FA, van Helden P, Harris CJ, Gordon R, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Sanz O, Santos G, Rebollo-Lopez MJ, Urones B, Selenski C, Lafuente-Monasterio MJ, Axtman M, Lelièvre J, Ballell L, Mueller R, Street LJ, Ghorpade SR, Chibale K.

J Med Chem. 2017 Dec 28;60(24):10118-10134. doi: 10.1021/acs.jmedchem.7b01347. Epub 2017 Dec 7.

14.

Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis.

Liang L, Shi R, Liu X, Yuan X, Zheng S, Zhang G, Wang W, Wang J, England K, Via LE, Cai Y, Goldfeder LC, Dodd LE, Barry CE, Chen RY.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1145-1149. doi: 10.5588/ijtld.16.0880.

PMID:
28911359
15.

Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.

Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, Yuan X, Mo X, Zhu H, Xu P, Gao Q, Lee M, Lee J, Smith LE, Chen RY, Joh JS, Cho Y, Liu X, Ruan X, Liang L, Dharan N, Cho SN, Barry CE 3rd, Ellner JJ, Dorman SE, Alland D.

N Engl J Med. 2017 Sep 14;377(11):1043-1054. doi: 10.1056/NEJMoa1614915.

16.

Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".

Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LAT, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01429-17. doi: 10.1128/AAC.01429-17. Print 2017 Sep. No abstract available.

17.

Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.

Santa Maria JP Jr, Park Y, Yang L, Murgolo N, Altman MD, Zuck P, Adam G, Chamberlin C, Saradjian P, Dandliker P, Boshoff HIM, Barry CE 3rd, Garlisi C, Olsen DB, Young K, Glick M, Nickbarg E, Kutchukian PS.

ACS Chem Biol. 2017 Sep 15;12(9):2448-2456. doi: 10.1021/acschembio.7b00468. Epub 2017 Aug 29.

PMID:
28806050
18.

Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c.

Moosa A, Lamprecht DA, Arora K, Barry CE 3rd, Boshoff HIM, Ioerger TR, Steyn AJC, Mizrahi V, Warner DF.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01338-17. doi: 10.1128/AAC.01338-17. Print 2017 Oct.

19.

Defective positioning in granulomas but not lung-homing limits CD4 T-cell interactions with Mycobacterium tuberculosis-infected macrophages in rhesus macaques.

Kauffman KD, Sallin MA, Sakai S, Kamenyeva O, Kabat J, Weiner D, Sutphin M, Schimel D, Via L, Barry CE 3rd, Wilder-Kofie T, Moore I, Moore R, Barber DL.

Mucosal Immunol. 2018 Mar;11(2):462-473. doi: 10.1038/mi.2017.60. Epub 2017 Jul 26.

20.

The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy.

Trauner A, Liu Q, Via LE, Liu X, Ruan X, Liang L, Shi H, Chen Y, Wang Z, Liang R, Zhang W, Wei W, Gao J, Sun G, Brites D, England K, Zhang G, Gagneux S, Barry CE 3rd, Gao Q.

Genome Biol. 2017 Apr 19;18(1):71. doi: 10.1186/s13059-017-1196-0.

21.

Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium.

Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526a. No abstract available.

PMID:
28388609
22.

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.

Nikiforov PO, Blaszczyk M, Surade S, Boshoff HI, Sajid A, Delorme V, Deboosere N, Brodin P, Baulard AR, Barry CE 3rd, Blundell TL, Abell C.

ACS Chem Biol. 2017 May 19;12(5):1390-1396. doi: 10.1021/acschembio.7b00091. Epub 2017 Apr 5.

23.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.

Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J; TBResist Global Genome Consortium, Chapman SB, Cho SN, Gabrielian A, Gomez J, Jodals AM, Joloba M, Jureen P, Lee JS, Malinga L, Maiga M, Nordenberg D, Noroc E, Romancenco E, Salazar A, Ssengooba W, Velayati AA, Winglee K, Zalutskaya A, Via LE, Cassell GH, Dorman SE, Ellner J, Farnia P, Galagan JE, Rosenthal A, Crudu V, Homorodean D, Hsueh PR, Narayanan S, Pym AS, Skrahina A, Swaminathan S, Van der Walt M, Alland D, Bishai WR, Cohen T, Hoffner S, Birren BW, Earl AM.

Nat Genet. 2017 Mar;49(3):395-402. doi: 10.1038/ng.3767. Epub 2017 Jan 16.

24.

Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.

Chakravorty S, Roh SS, Glass J, Smith LE, Simmons AM, Lund K, Lokhov S, Liu X, Xu P, Zhang G, Via LE, Shen Q, Ruan X, Yuan X, Zhu HZ, Viazovkina E, Shenai S, Rowneki M, Lee JS, Barry CE 3rd, Gao Q, Persing D, Kwiatkawoski R, Jones M, Gall A, Alland D.

J Clin Microbiol. 2016 Dec 28;55(1):183-198. doi: 10.1128/JCM.01771-16. Print 2017 Jan.

25.

Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes.

Costa DL, Namasivayam S, Amaral EP, Arora K, Chao A, Mittereder LR, Maiga M, Boshoff HI, Barry CE 3rd, Goulding CW, Andrade BB, Sher A.

MBio. 2016 Oct 25;7(5). pii: e01675-16. doi: 10.1128/mBio.01675-16.

26.

The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition.

Prosser G, Brandenburg J, Reiling N, Barry CE 3rd, Wilkinson RJ, Wilkinson KA.

Microbes Infect. 2017 Mar;19(3):177-192. doi: 10.1016/j.micinf.2016.10.001. Epub 2016 Oct 22. Review.

27.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee K, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons F, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Diaz GS, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Bösche M, Drewes G, Freiberg GM, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read K, Wyatt P, Barry CE 3rd, Boshoff HI.

ACS Infect Dis. 2017 Jan 13;3(1):18-33. doi: 10.1021/acsinfecdis.6b00103. Epub 2016 Oct 17.

28.

Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis.

Evans JC, Trujillo C, Wang Z, Eoh H, Ehrt S, Schnappinger D, Boshoff HI, Rhee KY, Barry CE 3rd, Mizrahi V.

ACS Infect Dis. 2016 Dec 9;2(12):958-968. Epub 2016 Oct 5.

29.

The Death of the "Three Ms".

Barry CE 3rd.

ACS Infect Dis. 2015 Dec 11;1(12):578-9. doi: 10.1021/acsinfecdis.5b00124. Epub 2015 Nov 16. No abstract available.

PMID:
27623054
30.

Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium, Lucas L, Spuy GV, Stanley K, Thiart L, Smith B, Du Plessis N, Beltran CG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Koegelenberg C, Vorster M, Griffith-Richards S.

Nat Med. 2016 Oct;22(10):1094-1100. doi: 10.1038/nm.4177. Epub 2016 Sep 5. Erratum in: Nat Med. 2017 Dec 7;23 (12 ):1499. Nat Med. 2017 Apr 7;23 (4):526.

31.

Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery.

Naran K, Moosa A, Barry CE 3rd, Boshoff HI, Mizrahi V, Warner DF.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6748-6757. doi: 10.1128/AAC.01178-16. Print 2016 Nov.

32.

Correction to Absolute Quantitative MALDI Imaging Mass Spectrometry: A Case of Rifampicin in Liver Tissues.

Chumbley CW, Reyzer ML, Allen JL, Marriner GA, Via LE, Barry CE 3rd, Caprioli RM.

Anal Chem. 2016 Sep 6;88(17):8920. doi: 10.1021/acs.analchem.6b03125. Epub 2016 Aug 19. No abstract available.

PMID:
27540623
33.

Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.

Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, Peppard T, Barry CE, Wang J, Dodd LE, Via LE, Barry CE 3rd, Walzl G, Alland D.

PLoS One. 2016 Aug 10;11(8):e0160062. doi: 10.1371/journal.pone.0160062. eCollection 2016.

34.

Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory site.

Kasbekar M, Fischer G, Mott BT, Yasgar A, Hyvönen M, Boshoff HI, Abell C, Barry CE 3rd, Thomas CJ.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7503-8. doi: 10.1073/pnas.1600630113. Epub 2016 Jun 20.

35.

The impact of social conditions on patient adherence to pulmonary tuberculosis treatment.

Choi H, Chung H, Muntaner C, Lee M, Kim Y, Barry CE, Cho SN.

Int J Tuberc Lung Dis. 2016 Jul;20(7):948-54. doi: 10.5588/ijtld.15.0759.

36.

2-Aryl-8-aza-3-deazaadenosine analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: Nucleoside antibiotics that block siderophore biosynthesis in Mycobacterium tuberculosis.

Krajczyk A, Zeidler J, Januszczyk P, Dawadi S, Boshoff HI, Barry CE 3rd, Ostrowski T, Aldrich CC.

Bioorg Med Chem. 2016 Jul 15;24(14):3133-43. doi: 10.1016/j.bmc.2016.05.037. Epub 2016 May 20.

37.

Inflammatory signaling in human tuberculosis granulomas is spatially organized.

Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE 3rd, Mann M, Dartois V, Rubin EJ.

Nat Med. 2016 May;22(5):531-8. doi: 10.1038/nm.4073. Epub 2016 Apr 4.

38.

Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.

Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, Follman D, Wang J, Cai Y, Goldfeder LC, Olivier KN, Xie Y, Via LE, Cho SN, Barry CE 3rd, Chen RY.

EBioMedicine. 2015 Oct 9;2(11):1627-33. doi: 10.1016/j.ebiom.2015.09.051. eCollection 2015 Nov.

39.

Absolute Quantitative MALDI Imaging Mass Spectrometry: A Case of Rifampicin in Liver Tissues.

Chumbley CW, Reyzer ML, Allen JL, Marriner GA, Via LE, Barry CE 3rd, Caprioli RM.

Anal Chem. 2016 Feb 16;88(4):2392-8. doi: 10.1021/acs.analchem.5b04409. Epub 2016 Feb 5. Erratum in: Anal Chem. 2016 Sep 6;88(17):8920.

40.

Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC).

Wood R, Morrow C, Barry CE 3rd, Bryden WA, Call CJ, Hickey AJ, Rodes CE, Scriba TJ, Blackburn J, Issarow C, Mulder N, Woodward J, Moosa A, Singh V, Mizrahi V, Warner DF.

PLoS One. 2016 Jan 25;11(1):e0146658. doi: 10.1371/journal.pone.0146658. eCollection 2016.

41.

Within patient microevolution of Mycobacterium tuberculosis correlates with heterogeneous responses to treatment.

Liu Q, Via LE, Luo T, Liang L, Liu X, Wu S, Shen Q, Wei W, Ruan X, Yuan X, Zhang G, Barry CE 3rd, Gao Q.

Sci Rep. 2015 Dec 1;5:17507. doi: 10.1038/srep17507.

42.

Treatment of Tuberculosis.

Horsburgh CR Jr, Barry CE 3rd, Lange C.

N Engl J Med. 2015 Nov 26;373(22):2149-60. doi: 10.1056/NEJMra1413919. Review. No abstract available.

PMID:
26605929
43.

Major Global Killer Tamed by Hydrogen.

Barry CE 3rd.

ACS Cent Sci. 2015 Sep 23;1(6):286-288. Epub 2015 Sep 3. No abstract available.

44.

Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization.

Soares de Melo C, Feng TS, van der Westhuyzen R, Gessner RK, Street LJ, Morgans GL, Warner DF, Moosa A, Naran K, Lawrence N, Boshoff HI, Barry CE 3rd, Harris CJ, Gordon R, Chibale K.

Bioorg Med Chem. 2015 Nov 15;23(22):7240-50. doi: 10.1016/j.bmc.2015.10.021. Epub 2015 Oct 22. Erratum in: Bioorg Med Chem. 2016 Jan 15;24(2):314. Candice, Soares de Melo [corrected to Soares de Melo, Candice].

PMID:
26522089
45.

Tuberculosis.

Dheda K, Barry CE 3rd, Maartens G.

Lancet. 2016 Mar 19;387(10024):1211-26. doi: 10.1016/S0140-6736(15)00151-8. Epub 2015 Sep 13. Review. Erratum in: Lancet. 2016 May 21;387(10033):2092. Lancet. 2016 Mar 19;387(10024):1162. Lancet. 2016 Mar 19;387(10024):1162.

PMID:
26377143
46.

Dynamic exometabolome analysis reveals active metabolic pathways in non-replicating mycobacteria.

Zimmermann M, Kuehne A, Boshoff HI, Barry CE 3rd, Zamboni N, Sauer U.

Environ Microbiol. 2015 Nov;17(11):4802-15. doi: 10.1111/1462-2920.13056. Epub 2015 Oct 14.

PMID:
26373870
47.

The association between sterilizing activity and drug distribution into tuberculosis lesions.

Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE 3rd, Dartois V.

Nat Med. 2015 Oct;21(10):1223-7. doi: 10.1038/nm.3937. Epub 2015 Sep 7.

48.

Mathematical Model of Oxygen Transport in Tuberculosis Granulomas.

Datta M, Via LE, Chen W, Baish JW, Xu L, Barry CE 3rd, Jain RK.

Ann Biomed Eng. 2016 Apr;44(4):863-72. doi: 10.1007/s10439-015-1415-3. Epub 2015 Aug 8.

49.

Linezolid for XDR-TB--Final Study Outcomes.

Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I.

N Engl J Med. 2015 Jul 16;373(3):290-1. doi: 10.1056/NEJMc1500286. No abstract available.

50.

Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis.

Nelson KM, Viswanathan K, Dawadi S, Duckworth BP, Boshoff HI, Barry CE 3rd, Aldrich CC.

J Med Chem. 2015 Jul 23;58(14):5459-75. doi: 10.1021/acs.jmedchem.5b00391. Epub 2015 Jul 9.

Supplemental Content

Loading ...
Support Center